Table 2. Univariate and multivariate analyses of factors associated with mortality or liver transplantation by week 24 of treatment.
| Comparison |
Univariate analyses |
Stepwise multivariate analyses |
|||
|---|---|---|---|---|---|
| Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | ||
| Age | per 1 year increase | 1.06 (0.99–1.13) | 0.105 | — | — |
| Sex | Male vs. female | 0.82 (0.09–7.28) | 0.853 | — | — |
| DM | Yes vs. no | 0.53 (0.06–4.77) | 0.574 | — | — |
| Hypertension | Yes vs. no | 6.91 (1.15–41.52) | 0.035 | — | — |
| Cirrhosis | Yes vs. no | 7.13 (1.19–42.96) | 0.032 | — | — |
| Glycyrrhizin | Yes vs. no | 0.25 (0.03–2.22) | 0.212 | — | — |
| NUC-naïve | Yes vs. no | 25.01 (0.00–1,810,741) | 0.572 | — | — |
| HBV-DNA | per log10 IU/ml increase | 1.45 (0.77–2.75) | 0.254 | — | — |
| AST | per 1 U/l increase | 1.00 (1.00–1.00) | 0.009 | — | — |
| ALT | per 1 U/l increase | 1.00 (1.00–1.00) | 0.115 | — | — |
| Albumin | per 1 g/dl increase | 0.27 (0.04–1.72) | 0.164 | — | — |
| Lactate | per 1 mg/dl increase | 1.02 (1.01–1.03) | 0.002 | — | — |
| MELD score | per score | 1.46 (1.18–1.80) | <0.001 | 1.98 (1.11–3.53) | 0.021 |
| Total bilirubin | per 1 mg/dl increase | 1.28 (1.09–1.49) | 0.002 | — | — |
| INR | Increase in ratio | 7.82 (3.01–20.29) | <0.001 | — | — |
| Creatinine | per 1 mg/dl increase | 9.18 (1.09–77.64) | 0.042 | — | — |
| Sodium | per 1 mmol/l increase | 0.89 (0.70–1.14) | 0.352 | — | — |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI; confidence interval; DM, diabetes mellitus; HBV, hepatitis B virus; INR, international normalized ratio of prothrombin time; MELD, model for end-stage liver disease; NUC, nucleos(t)ide analogs.